3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
309
Oxaliplatin
260
Leucovorin
234
Capecitabine
198
Irinotecan
147
Gemcitabine
128
Cisplatin
126
Bevacizumab
119
Radiotherapy
72
Paclitaxel
64
Folfox protocol
56
Cetuximab
56
Drug Therapy
46
Sorafenib
45
Docetaxel
42
S 1 (combination)
40
Chemotherapy, Adjuvant
38
Neoadjuvant Therapy
37
pembrolizumab
36
130-nm albumin-bound paclitaxel
29
Surgical Procedures, Operative
27
regorafenib
25
lenvatinib
24
XELOX
24
Radiation
24
Panitumumab
24
Nivolumab
23
atezolizumab
22
Carboplatin
22
trifluridine tipiracil drug combination
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
nanocis
×
Gastrointestinal
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled